See more : WayPoint Biomedical Holdings, Inc. (WYPH) Income Statement Analysis – Financial Results
Complete financial analysis of Incannex Healthcare Limited (IHL.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incannex Healthcare Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) Income Statement Analysis – Financial Results
- Presidio Property Trust, Inc. (SQFTW) Income Statement Analysis – Financial Results
- French Connection Group PLC (FCCN.L) Income Statement Analysis – Financial Results
- Afdeling Peruma Invest Globale Aktier (IAIPGA.CO) Income Statement Analysis – Financial Results
- Golden Power Group Holdings Limited (3919.HK) Income Statement Analysis – Financial Results
Incannex Healthcare Limited (IHL.AX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.incannex.com.au
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.01M | 782.38K | 1.90M | 604.88K | 1.18M | 1.01M | 282.05K | 0.00 | 0.00 | 0.00 | 35.74K | 66.32K | 0.00 | 26.18K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 6.34K | 911.97K | 450.35K | 582.21K | 524.08K | 516.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.01M | 776.05K | 985.63K | 154.54K | 596.26K | 488.15K | -234.45K | 0.00 | 0.00 | 0.00 | 35.74K | 66.32K | 0.00 | 26.18K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 99.19% | 51.94% | 25.55% | 50.60% | 48.23% | -83.13% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.36M | 5.37M | 4.65M | 2.11M | 736.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 568.95K | 7.43M | 3.44M | 1.78M | 1.90M | 2.47M | 3.07M | 513.63K | 542.31K | 862.28K | 2.04M | 2.26M | 2.77M | 447.05K | 694.53K | 912.92K | 1.06M |
| Selling & Marketing | 1.85M | 2.75M | 1.14M | 406.23K | 704.86K | 1.18M | 672.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.23M | 10.18M | 4.58M | 2.19M | 2.61M | 3.65M | 3.75M | 513.63K | 542.31K | 862.28K | 2.04M | 2.26M | 2.77M | 447.05K | 694.53K | 912.92K | 1.06M |
| Other Expenses | 0.00 | -782.38K | 73.07K | 212.63K | 1.80K | 12.77K | -17.94M | -41.70K | 10.73K | 5.82M | -2.09M | 66.32K | 44.64K | 4.53M | 149.76K | 426.77K | 6.85K |
| Operating Expenses | 21.36M | 14.77M | 9.22M | 4.30M | 3.38M | 3.71M | 3.78M | 772.94K | 2.50M | 6.68M | 10.99M | 3.40M | 4.68M | 1.91M | 4.01M | 1.34M | 1.12M |
| Cost & Expenses | 21.36M | 14.78M | 10.14M | 4.75M | 3.97M | 4.23M | 3.78M | 772.94K | 2.50M | 6.68M | 10.99M | 3.40M | 4.68M | 1.91M | 4.01M | 1.34M | 1.12M |
| Interest Income | 362.77K | 6.27K | 2.68K | 4.55K | 1.63K | 6.86K | 282.05K | 11.44K | 3.82K | 17.80K | 119.70K | 122.41K | 101.02K | 37.05K | 9.40K | 250.97K | 56.07K |
| Interest Expense | 0.00 | 9.12K | 0.00 | 0.00 | 85.07K | 12.88K | 55.67K | 81.43K | 119.87K | 174.34K | 190.60K | 189.03K | 95.01K | 122.19K | 47.70K | 12.21K | 6.43K |
| Depreciation & Amortization | 33.22K | 6.84M | 10.19M | 36.54K | 41.89K | 54.63K | 30.86K | 11.44K | 16.52K | 39.49K | 28.67K | 41.29K | 42.35K | 51.30K | 56.14K | 46.77K | 10.91K |
| EBITDA | -17.68M | -3.55M | -8.24M | -3.75M | -1.23M | -3.14M | -21.41M | -658.05K | -2.47M | -6.62M | -12.89M | -3.17M | -4.49M | 2.70M | -3.79M | -1.04M | -1.04M |
| EBITDA Ratio | -1,743.51% | -1,871.32% | -434.20% | -685.50% | -232.74% | -310.58% | -7,589.37% | 0.00% | 0.00% | 0.00% | -36,061.37% | -4,781.25% | 0.00% | 10,329.52% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.71M | -21.48M | -10.19M | -3.79M | -1.27M | -3.20M | -21.44M | -772.94K | -2.48M | -6.66M | -12.92M | -3.21M | -4.53M | 2.65M | -2.79M | -1.09M | -1.05M |
| Operating Income Ratio | -1,746.78% | -2,745.32% | -536.77% | -626.26% | -107.68% | -315.97% | -7,600.31% | 0.00% | 0.00% | 0.00% | -36,141.59% | -4,843.51% | 0.00% | 10,133.58% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.27M | -3.55M | -1.19M | -141.12K | -157.25K | -161.78K | -18.82M | -111.69K | -159.86K | -6.73M | -2.16M | -189.03K | -95.01K | 4.41M | -1.10M | -12.21K | -9.84K |
| Income Before Tax | -19.98M | -14.90M | -8.16M | -3.93M | -2.87M | -3.21M | -21.49M | -884.63K | -2.64M | -13.40M | -13.11M | -3.40M | -4.63M | 2.53M | -3.90M | -1.10M | -1.06M |
| Income Before Tax Ratio | -1,970.61% | -1,904.94% | -430.21% | -649.59% | -243.51% | -317.25% | -7,620.05% | 0.00% | 0.00% | 0.00% | -36,674.95% | -5,128.55% | 0.00% | 9,666.85% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.58M | -10.19M | 727.26K | -151.32K | -263.28K | -304.71K | -92.04K | -105.73K | -1.44M | -1.06M | -270.49K | 95.01K | 4.65M | -24.60K | 12.21K | 3.40K |
| Net Income | -19.98M | -8.32M | -8.16M | -4.70M | -2.72M | -2.95M | -21.49M | -792.59K | -2.54M | -11.96M | -12.05M | -3.13M | -4.63M | 2.53M | -3.87M | -1.10M | -1.06M |
| Net Income Ratio | -1,970.61% | -1,063.39% | -430.21% | -776.62% | -230.67% | -291.24% | -7,620.05% | 0.00% | 0.00% | 0.00% | -33,715.14% | -4,720.69% | 0.00% | 9,666.85% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.15 | -0.01 | -0.05 | -0.36 | -0.40 | -0.15 | -0.35 | 0.31 | -0.76 | -0.27 | -0.49 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.15 | -0.01 | -0.05 | -0.36 | -0.40 | -0.15 | -0.35 | 0.18 | -0.76 | -0.27 | -0.49 |
| Weighted Avg Shares Out | 1.54B | 1.19B | 976.93M | 684.04M | 447.44M | 250.23M | 141.93M | 69.57M | 48.43M | 33.24M | 30.01M | 21.18M | 13.20M | 8.05M | 5.09M | 4.14M | 2.17M |
| Weighted Avg Shares Out (Dil) | 1.54B | 1.19B | 976.93M | 684.04M | 447.44M | 250.23M | 141.93M | 69.57M | 48.43M | 33.24M | 30.01M | 21.18M | 13.20M | 13.86M | 5.09M | 4.14M | 2.17M |
Source: https://incomestatements.info
Category: Stock Reports